Retrospective analysis results demonstrated that lurbinectedin shows promise as a potential new second-line option for patients with platinum-sensitive small cell lung cancer who experience relapse after platinum-based treatment.
Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.
Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.
Stay updated with the latest on the MSK and Anthem Blue Cross insurance negotiations to keep Memorial Sloan Kettering Cancer Center as an in-network provider.
Head of Kamal Adwan hospital says it is ‘next to impossible’ to obey shut down order due to lack of ambulances to evacuate patients
Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.
In this issue of Blood, Verkamp and colleagues1 present a retrospective analysis of the emapalumab (anti-interferon gamma [IFN-γ] monoclonal antibody) use
PURPOSERemote symptom monitoring of patients with cancer has previously shown potential for improving clinical outcomes. This study aimed to evaluate the effects of remote symptom…
Nicholas Silvestri, MD, of the Univ of Buffalo, provides an overview of the latest myasthenia gravis clinical research presented at AAN 2024.
The Childhood Cancer Data Initiative addresses the critical need to collect, analyze, and share data to speed up progress against childhood cancer.
Join the world’s leading hematology experts at Highlights of ASH in the Mediterranean, Middle East, and North Africa, a two-day program that highlights the most…
